Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.38 |
| ▸ | PPARA | Q07869 | 1/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.38 |
| ▸ | YEATS4 | O95619 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 3/20 | 0.36 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.36 |
| ▸ | F2 | P00734 | 1/20 | 0.34 |
| ▸ | DAO | P14920 | 1/20 | 0.34 |
| ▸ | NPC1 | O15118 | 2/20 | 0.33 |
| ▸ | RAB9A | P51151 | 2/20 | 0.33 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 2/20 | 0.33 |
| ▸ | AR | P10275 | 2/20 | 0.33 |
| ▸ | HTT | P42858 | 2/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.33 |
| ▸ | GSK3B | P49841 | 1/20 | 0.31 |
| ▸ | HSD17B1 | P14061 | 1/20 | 0.31 |
| ▸ | HSD17B2 | P37059 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6637594 | 0.82 | F2 (0.38) | PPARATSHRF2DAOLMNA | |
| SCHEMBL22096340 | 0.81 | PPARA (0.33) | KMT2APPARARAB9AHTTSMN1; SMN2 | |
| SCHEMBL19413743 | 0.80 | TSHR (0.38) | PPARATSHRF2DAONPC1 | |
| SCHEMBL47581 | 0.80 | MAPK1 (0.45) | KMT2AMAPK1YEATS4TSHRMAPK14 | |
| SCHEMBL12691851 | 0.77 | ALDH1A1 (0.36) | KMT2APPARAMAPK1TSHRF2 | |
| SCHEMBL24346237 | 0.75 | PPARA (0.37) | KMT2APPARAMAPK1TSHRF2 | |
| SCHEMBL9036699 | 0.75 | AR (0.38) | PPARATSHRAR | |
| SCHEMBL6990461 | 0.75 | TAAR1 (0.39) | PPARATSHRF2GSK3B | |
| SCHEMBL19413714 | 0.73 | MEN1 (0.35) | KMT2APPARATSHRHTTMEN1 | |
| SCHEMBL12737778 | 0.72 | MAPK1 (0.41) | KMT2AMAPK1YEATS4TSHRMAPK14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 244 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12043613-B2 | Inhibitors of SARM1 | DISARM THERAPEUTICS, INC. (US) | 2024-07-23 | — | — | US | disclosed |
| US-12043613-B2 | Inhibitors of SARM1 | DISARM THERAPEUTICS, INC. (US) | 2024-07-23 | — | — | US | disclosed |
| US-11807624-B2 | Substituted pyrimidinones as agonists of the APJ receptor | AMGEN INC. (US) | 2023-11-07 | — | — | US | disclosed |
| US-11807624-B2 | Substituted pyrimidinones as agonists of the APJ receptor | AMGEN INC. (US) | 2023-11-07 | — | — | US | disclosed |
| US-11807641-B2 | MASP-2 inhibitors and methods of use | OMEROS CORPORATION (US) | 2023-11-07 | — | — | US | disclosed |
| US-11807641-B2 | MASP-2 inhibitors and methods of use | OMEROS CORPORATION (US) | 2023-11-07 | — | — | US | disclosed |
| US-20230348501-A1 | HETEROARYL INHIBITORS OF PDE4 | Tetra Discovery Partners, LLC | 2023-11-02 | — | — | US | disclosed |
| US-20230348501-A1 | HETEROARYL INHIBITORS OF PDE4 | Tetra Discovery Partners, LLC | 2023-11-02 | — | — | US | disclosed |
| US-20230322721-A1 | TRIAZOLE DERIVATIVES AND THEIR USE AS TANKYRASE INHIBITORS | UNIVERSITY OF OULU (FI) | 2023-10-12 | — | — | US | disclosed |
| US-20230322721-A1 | TRIAZOLE DERIVATIVES AND THEIR USE AS TANKYRASE INHIBITORS | UNIVERSITY OF OULU (FI) | 2023-10-12 | — | — | US | disclosed |
| US-7361669-B2 | Compositions and method for inhibiting TGF-β | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2008-04-22 | — | — | US | disclosed |
| US-7358257-B2 | sulfonylurea derivatives, sulfonylthiourea derivatives, sulfonylguanidine derivatives, sulfonylcyanoguanidine derivatives, thioacylsulfonamide derivatives, and acylsulfonamide derivatives; effective for prevention and treatment of cardiovascular diseases, antithrombotic agents | PORTOLA PHARMACEUTICALS, INC. (US) | 2008-04-15 | — | — | US | disclosed |
| US-20070244117-A1 | Novel Hydroxamic Acid Esters and Pharmaceutical Use Thereof | LEO PHARMA A/S (DK) | 2007-10-18 | — | — | US | disclosed |
| US-20070225365-A1 | Cetp Inhibitors | MERCK & CO., INC. (US) | 2007-09-27 | — | — | US | disclosed |
| US-20070179167-A1 | Inhibitors of serine proteases | VERTEX PHARMACEUTICALS INCORPORATED | 2007-08-02 | — | — | US | disclosed |
| US-20070066598-A1 | Compounds | BIOVITRUM AB, A SWEDEN CORPORATION | 2007-03-22 | — | — | US | disclosed |
| US-20070066599-A1 | New compounds | BIOVITRUM AB, A SWEDEN CORPORATION | 2007-03-22 | — | — | US | disclosed |
| US-20070066599-A1 | New compounds | BIOVITRUM AB, A SWEDEN CORPORATION | 2007-03-22 | — | — | US | disclosed |
| US-20070066600-A1 | Compounds | PROXIMAGEN NEUROSCIENCE PLC (GB) | 2007-03-22 | — | — | US | disclosed |
| US-20070066600-A1 | Compounds | PROXIMAGEN NEUROSCIENCE PLC (GB) | 2007-03-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070066599-A1 | New compounds | SULT2A1, GPR119, STS | KMT2A 2359/4885PPARA 60/4885MAPK1 1390/4885 |
| US-20070225365-A1 | Cetp Inhibitors | CETP, APOB, NPC1 | KMT2A 2229/4885PPARA 350/4885MAPK1 2498/4885 |
| US-11807641-B2 | MASP-2 inhibitors and methods of use | MASP2, METAP2, SPINT2 | KMT2A 2885/4885PPARA 4720/4885MAPK1 2973/4885 |
| US-20230322721-A1 | TRIAZOLE DERIVATIVES AND THEIR USE AS TANKYRASE INHIBITORS | CBR3, GBA3, TECR | KMT2A 4173/4885PPARA 3896/4885MAPK1 1823/4885 |
| US-20070066598-A1 | Compounds | SULT2A1, STS, SLC5A2 | KMT2A 1776/4885PPARA 73/4885MAPK1 1690/4885 |
| US-20230348501-A1 | HETEROARYL INHIBITORS OF PDE4 | PDE4A, PDE4B, PDE4C | KMT2A 3408/4885PPARA 810/4885MAPK1 2441/4885 |
| US-12043613-B2 | Inhibitors of SARM1 | SARM1, SMN1; SMN2, SARNP | KMT2A 3434/4885PPARA 4442/4885MAPK1 1113/4885 |
| US-20070066600-A1 | Compounds | SULT2A1, STS, SLC5A2 | KMT2A 1776/4885PPARA 73/4885MAPK1 1690/4885 |
| US-20070179167-A1 | Inhibitors of serine proteases | PRSS1, PRSS3, PRSS2 | KMT2A 3222/4885PPARA 4490/4885MAPK1 971/4885 |
| US-20070244117-A1 | Novel Hydroxamic Acid Esters and Pharmaceutical Use Thereof | F9, F12, HDAC9 | KMT2A 1452/4885PPARA 1123/4885MAPK1 4401/4885 |
| US-11807624-B2 | Substituted pyrimidinones as agonists of the APJ receptor | APLNR, AGTR1, AGTR2 | KMT2A 4021/4885PPARA 111/4885MAPK1 1088/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.